Coagulation management in major trauma

Summary

Bleeding is a common problem in major trauma. Coagulopathy could be detected in approximately 25% of all trauma patients on arrival in the emergency room. The reasons for that are blood loss, dilution of the remaining coagulation factors by fluids not containing coagulation factors, consumption of coagulation factors and hyperfibrinolysis. Hypothermia and acidosis are also well described contributors of coagulopathy.

Diagnosis of coagulation abnormalities should be based on clinical judgement. Standard coagulation tests are universally available, but there is some evidence, that those tests are not predictive for transfusion requirement. Thrombelastography/ metry is a promising technology which not only shows the initiation of the coagulation process but also the dynamic of clot formation and the clot firmness. It is the golden standard for the diagnosis of hyperfibrinolysis. To restore adequate haemostasis an aggressive treatment of hypothermia and acidosis is essential. The concept of damage control surgery and permissive hypotension in server bleeding patients could reduce the whole amount of blood loss.

For coagulation factor replacement therapy fresh frozen plasma, PCC, fibrinogen concentrates and cryoprecipitate could be used. Haematocrit should be maintained in the range of 30% and platelet count should not drop below 50 000/μl. In some circumstances haemostatic agents such as DDAVP, antifibrinolytics and rFVIIa could be helpful, even there is no conclusive evidence for the use of these drugs in severe trauma patients.

Keywords

Coagulation management - coagulopathy - major trauma

• References

• 1 Armand R, Hess JR. Treating coagulopathy in trauma patients. Transfus Med Rev 2003; 17: 223-231.
• 2 Barletta JF, Ahrens CL, Tyburski JG. et al. A review of recombinant factor VII for refractory bleeding in nonhemophilic trauma patients. J Trauma 2005; 58: 646-651.
• 3 Boffard KD, Riou B, Warren B. et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-15.
• 4 Brohi K, Singh J, Heron M. et al. Acute traumatic coagulopathy. J Trauma 2003; 54: 1127-1130.
• 5 Chowdhury P, Saayman AG, Paulus U. et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125: 69-73.
• 6 Contreras M. The appropriate use of platelets: an update form the Edinburgh Consensus Conference. Br J Haematol 1998; 101 (Suppl. 01) 10-12.
• 7 Cosgriff N, Moore EE, Sauaia A. et al. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidosis revisited. J Trauma 1997; 42: 857-861.
• 8 Dara SI, Rana R, Afessa B. et al. Fresh frozen plasma transfusion in critically ill medical patients with coagulopathy. Crit Care Med 2005; 33: 2667-2671.
• 9 Dutton RP, Mackenzie CF, Scalea TM. Hypotensive resuscitation during active hemorrhage: impact on in-hospital mortality. J Trauma 2002; 52: 1141-1146.
• 10 Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep 2004; 3: 324-330.
• 11 Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 2006; 19: 97-112.
• 12 Fries D, Innerhofer P, Schobersberger W. Coagulation Management in trauma patients. Curr Opin Anaesthesiol 2002; 15: 217-223.
• 13 Fries D, Innerhofer P, Klingler A. et al. The effect of the combined administration of colloids and lactated Ringer’s solution on the coagulation system: an in vitro study using thrombelastograph coagulation analysis (ROTEG). Anesth Analg 2002; 94: 1280-1287.
• 14 Gonzalez E, Moor FA, Holcomb JB. et al. Fresh frozen plasma should be given earlier to patients requiring massive transfusion. J Trauma 2007; 62: 112-117.
• 15 Hardy JF, Moerloose P, Samama M. Massive transfusion and coagulopathy: pathophysiology and implications for clinical management. Can J Anaesth 2004; 51: 293-310.
• 16 Heindl B, Delorenzo C, Spannagl M. High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion. Anaesthesist 2005; 54: 787-790.
• 17 Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81: 360-365.
• 18 Hirshberg A, Dugas M, Banez EI. et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54: 454-463.
• 19 Ho AM, Karmakar MK, Dion PW. Are we giving enough coagulation factors during major trauma resuscitation?. Am J Surg 2005; 190: 479-484.
• 20 Johnson JW, Gracias VH, Schwab CW. et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma 2001; 51: 261-269.
• 21 Jurkovich GJ, Greiser WB, Luterman A. et al. Hypothermia in trauma victims: an ominous predictor of survival. J Trauma 1987; 27: 1019-1024.
• 22 Kaufmann CR, Dwyer KM, Crews JD. et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42: 716-720.
• 23 Kitchens CS. To bleed or not to bleed?. Is that the question for the PTT? J Thromb Haemost 2005; 3: 2607-2611.
• 24 Lampl L, Seifried E, Tisch M. et al. Hemostatic disorders following polytrauma – the role of physiologic coagulation inhibitors during the preclinical phase. Anasthesiol Intensivmed Notfallmed Schmerzther 1992; 27: 31-36.
• 25 Lawson J, Murphy M. Challenges for providing effective hemostasis in surgery and trauma. Semin Hematol 2004; 41 1Suppl 1 55-64.
• 26 Levi M. Pro-haemostatic therapy for prevention and treatment of bleeding. In: Vincent JL. (ed). Yearbook of Intensive Care and Emergency Medicine. Heidelberg: Springer; 2002: 649-660.
• 27 Martini WZ, Pusateri AE, Uscilowicz JM. et al. Independent contributions of hypothermia and acidosis to coagulopathy in swine. J Trauma 2005; 58: 1002-1009.
• 28 Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rVIIa Task Force. J Thromb Haemost 2005; 3: 640-648.
• 29 Meng ZH, Wolberg AS, Monroe DM. et al. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55: 886-891.
• 30 O´Shaughnessy DF, Atterbury C, Bolton Maggs P. et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126: 11-28.
• 31 Quaknine-Orlando B, Samama CM, Riou B. et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology 1999; 90: 1454-1461.
• 32 Rohrer MJ, Natale AM. Effect of hypothermia on the coagulation cascade. Crit Care Med 1992; 20: 1402-1405.
• 33 Sauaia A, Moore FA, Moore EE. et al. Epidemiology of trauma deaths: a reassessment. J Trauma 1995; 38: 185-193.
• 34 Siffert W. Regulation of platelet function by sodium- hydrogen exchange. Cardiovasc Res 1995; 29: 160-166.
• 35 Toy P, Popovsky MA, Abraham E. et al. Transfusion- related acute lung injury: definition and review. Crit Care Med 2005; 33: 721-726.
• 36 Valeri CR, Cassidy G, Pivacek LE. et al. Anemiainduced increase in the bleeding time: implications for treatment of nonsurgical blood loss. Transfusion 2001; 41: 977-983.
• 37 Valeri CR, Feingold H, Cassidy G. et al. Hypothermia- induced reversible platelet dysfunction. Ann Surg 1987; 205: 175-181.
• 38 Wilson RF, Dulchavsky SA, Soullier G. et al. Problems with 20 or more blood transfusions in 24 hours. Am Surg 1987; 53: 410-417.
• 39 Wolberg AS, Meng ZH, Monroe 3rd DM. et al. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56: 1221-1228.
• 40 Yenari M, Palmer J, Bracci P. et al. Thrombolysis with tissue plasminogen activator (tPA) is temperature dependent. Thromb Res 1995; 77: 475-481.